USCOM LIMITED — Capital/Financing Update 2021

Jul 6, 2021

ASX MEDIA RELEASE

Amended: Russian Regulatory Approval and Distribution for USCOM 1A

• Russian regulatory certification for USCOM 1A Cardiac Monitor - Russia a significant and growing European market - Uscom continues global expansion

SYDNEY, Australia, Wednesday 7[th] July 2021: Uscom Limited (ASX code: UCM) (the Company or Uscom ) today notified the market that the USCOM 1A has received Russian Certification of Registration for sale into the Russian market. The regulatory process is usually 12-18 months but took approximately 3 years following delays with the COVID pandemic. Uscom has worked closely with our experienced Russian distributor, Wondermed, to successfully manage this protracted regulatory process.

Background:

Russia has a population of ~150m and the world’s 12th largest GDP at ~$1.3T USD, and a medical health spend of 3.5% (~$45B USD). The medical market in Russia is anticipated to grow as the population continues to age and community health care expectations increase. In Russia medical devices for diagnostic or therapeutic applications must be registered at the central department of the Federal Service on surveillance in Healthcare and Social Development (Roszdravnadzor) in Moscow. After a period of evaluation and testing, Roszdravnadzor issues the certificate of registration permitting sale of the product in Russia.

Operations:

Uscom’s appointed Russian distributor, Wondermed, previously known as VOK Medical, has excellent local connections in critical care and paediatrics, and is experienced in Russian medical capital sales. Wondermed is now responsible for the importation and distribution of the USCOM 1A throughout Russia. Submission for BP+ and SpiroSonic is also being planned.

Commentary:

Executive Chairman of Uscom, Professor Rob Phillips said “Uscom’s growth continues to be strong despite the pandemic, and our strategy for incremental growth is simply more products, more distributors and more revenue, and we are delivering on this plan. Russia is a significant addition to our global network of countries that Uscom is approved to export into. In the last 2 months we have received CE for SpiroSonic AIR in Europe and SE Asia, NMPA for BP+ in China, and now USCOM 1A approval in Russia. Combined with impending US FDA approvals for SpiroSonic and BP+, our “product regions” will have more than doubled over 12 months. For investors, what was once an ambitious and complex global strategy is becoming increasingly simple as Uscom continues growing operations and revenues by increasing products, regions and distributors, and builds a prosperous multi-product global business.”

Uscom devices:

Uscom manufactures and markets the USCOM 1A haemodynamic monitor, the Uscom BP+ , central blood pressure and vascular health monitor, the Uscom SpiroSonic digital ultrasonic spirometers, and the VENTITEST and VENTITEST-S ultrasonic ventilator calibrators for optimising respiratory device performance.

Uscom Limited (ABN 35 091 028 090) Suite 2, Level 8, 66 Clarence Street, Sydney, NSW, 2000, Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au

ASX MEDIA RELEASE

About Uscom

Uscom Limited (UCM) : An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A : A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+ : A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary BP+ Reporter , an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

Uscom SpiroSonic digital multi-path ultrasonic spirometers : High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They require no calibration, are simple to disinfect, and are simple and accurate to use providing research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone apps and proprietary SpiroSonic software, SpiroReporter , with wireless interfacing to provide remote telemonitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, occupational lung disease and monitoring of pulmonary therapeutic compliance.

VENTITEST digital ultrasonic ventilator testing solution is a new system for testing ventilators. All ventilators require calibration to maintain the accuracy with which they measure the pressure, flow and volume of air they deliver. VENTITEST and VENTITEST-S, based on advanced SpiroSonic technology provides a testing solution that provides for simple and accurate testing, archiving, analysis and reporting to optimise ventilation performance.

For more information, please visit: www.uscom.com.au

Uscom Contacts Rob Phillips Chairman rob@uscom.com.au

Brett Crowley Company Secretary

Uscom Limited (ABN 35 091 028 090) Suite 2, Level 8, 66 Clarence Street, Sydney, NSW, 2000, Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au